Birdwatch Archive

Birdwatch Note

2023-03-12 17:14:05 UTC - MISINFORMED_OR_POTENTIALLY_MISLEADING

The FDA publishes the 503B Bulks List, a list of active pharmaceutical ingredients. Some of the items on this list were recommended to be included, but none received adequate support, meaning that these compounds have NOT been rebranded as “substances.” https://www.fda.gov/media/94164/download https://www.federalregister.gov/documents/2022/01/27/2022-01558/list-of-bulk-drug-substances-for-which-there-is-a-clinical-need-under-section-503b-of-the-federal

Written by 873F3C7468C0790B61E29ECBA910F835731B69126F882CF1F21456FC66F41E7B
Participant Details

Original Tweet

Tweet embedding is no longer reliably available, due to the platform's instability (in terms of both technology and policy). If the Tweet still exists, you can view it here: https://twitter.com/foo_bar/status/1634675692981092353

Please note, though, that you may need to have your own Twitter account to access that page. I am currently exploring options for archiving Tweet data in a post-API context.

All Information

  • ID - 1634966000226402304
  • noteId - 1634966000226402304
  • participantId - 873F3C7468C0790B61E29ECBA910F835731B69126F882CF1F21456FC66F41E7B
  • noteAuthorParticipantId -
  • createdAtMillis - 1678641245309
  • tweetId - 1634675692981092353
  • classification - MISINFORMED_OR_POTENTIALLY_MISLEADING
  • believable -
  • harmful -
  • validationDifficulty -
  • misleadingOther - 0
  • misleadingFactualError - 1
  • misleadingManipulatedMedia - 0
  • misleadingOutdatedInformation - 0
  • misleadingMissingImportantContext - 1
  • misleadingUnverifiedClaimAsFact - 1
  • misleadingSatire - 0
  • notMisleadingOther - 0
  • notMisleadingFactuallyCorrect - 0
  • notMisleadingOutdatedButNotWhenWritten - 0
  • notMisleadingClearlySatire - 0
  • notMisleadingPersonalOpinion - 0
  • trustworthySources - 1
  • summary
    • The FDA publishes the 503B Bulks List, a list of active pharmaceutical ingredients. Some of the items on this list were recommended to be included, but none received adequate support, meaning that these compounds have NOT been rebranded as “substances.” https://www.fda.gov/media/94164/download https://www.federalregister.gov/documents/2022/01/27/2022-01558/list-of-bulk-drug-substances-for-which-there-is-a-clinical-need-under-section-503b-of-the-federal

Note Status History

createdAt timestampMillisOfFirstNonNMRStatus firstNonNMRStatus timestampMillisOfCurrentStatus currentStatus timestampMillisOfLatestNonNMRStatus mostRecentNonNMRStatus participantId
2023-03-12 17:14:05 UTC
(1678641245309)
1969-12-31 23:59:59 UTC
(-1)
2023-03-13 02:08:35 UTC
(1678673315039)
NEEDS_MORE_RATINGS 1969-12-31 23:59:59 UTC
(-1)

Note Ratings

rated at rated by
2023-03-12 18:45:44 -0500 081E40DD9D6FE456EA6E427DDDD80A03269B6088B0556BA2D5FA37D97E890EDE Rating Details
2023-03-12 14:09:49 -0500 3922021E2B4C1A4B610B8FAFE0447925B4441B7A397CBAE1E446B9DE65C2A8E3 Rating Details
2023-03-12 13:07:03 -0500 45060ED935D102E05C21C743FE433C0B17B27D8FCF69CED01A2AD3F9AB2815B1 Rating Details
2023-03-12 13:18:02 -0500 464F514091F013106E190C712492FDDD7A2F35D38B0E762F31374CC21B9FD858 Rating Details
2023-03-12 13:14:04 -0500 60CA16F021BFF5F46E779702FDD20F5F5038764BDB8C232B3E5EB692C88A3F38 Rating Details
2023-03-12 17:04:14 -0500 77970E3BCBC3225621F0B02418F03B8FF013C6AE18E33EFF939C51AD5AE32792 Rating Details
2023-03-12 18:09:35 -0500 B289B7B9A72A2B21A5016714B5CFECC892B67D4EF528AD49D229201250F7B83A Rating Details
2023-03-12 16:26:05 -0500 B5FEE1C7F02671E2466AE0184315222BE9F827034DA0D608839BE86F8B7D554A Rating Details
2023-03-14 06:49:00 -0500 Rating Details
2023-03-13 11:02:19 -0500 Rating Details
2023-03-13 10:36:15 -0500 Rating Details
2023-03-13 10:23:34 -0500 Rating Details
2023-03-13 10:14:11 -0500 Rating Details
2023-03-13 10:01:46 -0500 Rating Details
2023-03-13 09:51:21 -0500 Rating Details
2023-03-13 09:37:03 -0500 Rating Details
2023-03-13 09:22:31 -0500 Rating Details
2023-03-13 09:21:49 -0500 Rating Details
2023-03-13 08:59:25 -0500 Rating Details
2023-03-13 08:58:51 -0500 Rating Details
2023-03-13 08:48:15 -0500 Rating Details
2023-03-13 08:10:50 -0500 Rating Details
2023-03-13 08:05:31 -0500 Rating Details
2023-03-13 04:31:21 -0500 Rating Details
2023-03-16 12:19:38 -0500 Rating Details
2023-03-15 23:05:50 -0500 Rating Details
2023-03-21 22:56:16 -0500 Rating Details
2023-04-05 15:30:47 -0500 Rating Details
2023-03-13 10:01:46 -0500 Rating Details
2023-03-13 08:58:51 -0500 Rating Details
2023-03-13 09:37:03 -0500 Rating Details
2023-03-12 17:04:14 -0500 Rating Details
2023-03-15 23:05:50 -0500 Rating Details
2023-03-16 12:19:38 -0500 Rating Details
2023-03-13 10:36:15 -0500 Rating Details
2023-03-13 08:10:50 -0500 Rating Details
2023-03-12 16:26:05 -0500 Rating Details
2023-03-13 04:31:21 -0500 Rating Details
2023-03-12 13:07:03 -0500 Rating Details
2023-03-13 08:48:15 -0500 Rating Details
2023-03-12 18:45:44 -0500 Rating Details
2023-03-12 13:14:04 -0500 Rating Details
2023-03-13 08:59:25 -0500 Rating Details
2023-03-12 14:09:49 -0500 Rating Details
2023-03-13 10:14:11 -0500 Rating Details
2023-03-12 13:18:02 -0500 Rating Details
2023-03-13 09:21:49 -0500 Rating Details
2023-03-12 18:09:35 -0500 Rating Details
2023-03-13 08:05:31 -0500 Rating Details
2023-03-13 11:02:19 -0500 Rating Details
2023-03-14 06:49:00 -0500 Rating Details
2023-03-13 09:22:31 -0500 Rating Details
2023-03-21 22:56:16 -0500 Rating Details
2023-03-13 09:51:21 -0500 Rating Details
2023-03-13 10:23:34 -0500 Rating Details
2023-04-05 15:30:47 -0500 Rating Details